Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Keyword
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 1 Component(s) Recorded On: 10/24/2023

    The second iteration of the SIO Bone Club, hosted during 2023 IO Awareness Week. Faculty review cases and discuss treatment options, device selection and usage, tips and tricks, and lessons learned from their own experiences. This webinar is jointly supported by BD, Boston Scientific, Stryker, and Varian Medical Systems.

    The second iteration of the SIO Bone Club, hosted during 2023 IO Awareness Week. Faculty review cases and discuss treatment options, device selection and usage, tips and tricks, and lessons learned from their own experiences. This webinar is jointly supported by BD, Boston Scientific, Stryker, and Varian Medical Systems.

    Moderators: 

    • Sean M. Tutton, MD, FSIR, FCIRSE, SIO Education Advisor, Professor of Radiology and Orthopedics, UC San Diego
    • Jack Jennings, MD, PhD, SIO Treasurer, Professor and Chief of Musculoskeletal Radiology, Washington University St. Louis


    Faculty: 

    • Tony Brown, MD, Interventional Radiologist, Radiology Imaging Associates Endovascular
    • Scott J. Genshaft, MD, Interventional and Diagnostic Radiologist, UCLA Health
    • Marwan Moussa, MD, Instructor of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School
    • Alan Alper Sag, MD, Assistant Professor of Interventional Radiology and Orthopaedic Surgery, Duke University Medical Center
  • Contains 1 Component(s)

    The Society of Interventional Oncology (SIO) and The France Foundation (TFF) have partnered to develop this educational initiative. This interactive module features an expert panel representing medical and interventional oncology reviewing patient cases in a tumor board format.

    The Society of Interventional Oncology (SIO) released a 2019 white paper on immunotherapy and interventional oncology (IO) that stated, “The role of immunotherapy in cancer care is rapidly developing, and immunotherapy will continue to be a key player in improving cancer care. As our role as interventional oncologists in relation to immunomodulation continues to take shape, multiple questions and challenges exist for determining some of the optimal approaches and implementing immunotherapy into practice.”5 Multidisciplinary management of HCC and other cancers has become a given in medicine. IOs must be cognizant of the rapidly evolving role of immunotherapy in the management of HCC, alone, in combination, and with loco-regional interventional therapies.

     The Society of Interventional Oncology (SIO) is committed to advancing the role of interventional oncology to enhance the traditional pillars of cancer treatment: surgery, radiotherapy, and chemotherapy to deliver personalized treatment plans. Working in multidisciplinary teams, IOs play an important role in determining the best course of treatment. It is essential to ensure that these clinicians are up to date with the latest clinical trial results and ongoing research on advances in HCC therapeutic agents to understand current and potential options throughout the course of the disease. 

  • Contains 1 Component(s)

    A 100-level MSK-focused webinar recorded 16 May 2023.

    In this 100-level MSK-focused webinar. Faculty will provide an overview of the Stryker OptaBlate bone tumor ablation tool and discuss bone tumor ablation cases submitted by attendees. This webinar is sponsored by Stryker.

    Faculty:
    Moderator: Sean Tutton, MD, FSIR, FCIRSE (Professor of Radiology and Orthopedics, UCSD Health)
    Moderator: Jack Jennings, MD, PhD (Professor of Radiology, Washington University School of Medicine)
    Brandon Key, MD (Assistant Professor, Medical College of Wisconsin)
    Rahul Sheth, MD (Associate Professor, MD Anderson Cancer Center)
    Steven Yevich, MD (Assistant Professor, MD Anderson Cancer Center)

  • Contains 1 Component(s)

    This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings.

    LEARNING OBJECTIVES

    Upon completion of this course, the learners should be able to:
    • Apply strategies for early and accurate diagnosis of HCC stages
    • Summarize mechanisms of action and clinical profiles of new and emerging immuno-oncology (IO) agents (mono and combo) for each stage of HCC
    • Analyze data on IO therapy with liver-directed therapy procedures to identify appropriate patients
    • Describe the role of HCC care team members and explain techniques to increase communication and collaboration

    FACULTY 
    Rony Avritscher, MD, FSIR
    Department of Interventional Radiology
    Professor of Interventional Radiology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Ahmed Omar Kaseb, MD, CMQ
    John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research
    Member, National Hepatobiliary Task Force, NCI, USA
    Tenured Professor and Director, Hepatocellular Carcinoma Program
    Director, MD Anderson HCC SPORE
    Editor-in-Chief, Journal of Hepatocellular Carcinoma 
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    PLANNING COMMITTEE
    Adam Burgoyne, MD, PhD
    Chair of the Steering Committee
    Associate Clinical Professor
    Department of Medicine
    Division of Hematology/Oncology
    University of California, San Diego
    San Diego, California

    Amit Singal, MD
    Medical Director of the Liver Tumor Program
    Clinical Chief of Hepatology
    Professor of Internal Medicine
    UT Southwestern Medical Center 
    Dallas, Texas

    Cindi Cantril, MPH, RN, OCN, CBCN
    Cancer Resources Recovery
    Geyersville, California

    Isabel Newton, MD, PhD
    Department of Radiology
    Assistant Professor of Radiology
    University of California, San Diego
    San Diego, California

    Rony Avritscher, MD, FSIR
    Department of Interventional Radiology
    Professor of Interventional Radiology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Sarah Manes, MS, CCLS
    Liver Cancers Program Director
    Global Liver Institute
    Washington, DC

    Stacey Stein, MD
    Associate Professor of Internal Medicine
    Assistant Medical Director, Clinical Trials Office
    Yale Medicine
    New Haven, Connecticut

    Patrick Harty, PhD
    Medical Director
    The France Foundation

    INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
    There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pre-test, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the post-test is required to successfully complete this activity. The participant may take the test until successfully passed.

    Credit fulfillment
    • If you are requesting AMA credits, ANCC credits, or a certificate of participation your certificate will be available for download 

    Technical Requirements 
    This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers.
    Additionally, this site and its activities are best viewed using the latest operating system for your device.

    ACCREDITED PROVIDER 

    This activity is jointly provided by The France Foundation and Society for Interventional Oncology.
      

    Accreditation Statement 

    In support of improving patient care, this activity has been planned and implemented by The France Foundation and Society for Interventional Oncology. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    PHYSICIAN CREDIT DESIGNATION
    The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES
    The France Foundation designates this activity for 1.0 contact hours.

    All other healthcare professionals completing this course will be issued a statement of participation.

    DISCLOSURE POLICY

    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and Society for Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Disclosure of Unlabeled Use:

    TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information. 

    COMMERCIAL SUPPORT ACKNOWLEDGMENT
    This activity is supported by an educational grant from AstraZeneca.

    Disclaimer
    The France Foundation and Society for Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Society for Interventional Oncology, and the commercial supporter(s) assume no liability for the information herein.

    COPYRIGHT INFORMATION
    Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions: 
    • The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered. 
    • Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission 

    PRIVACY POLICY
    The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.

    The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

    Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy. 

    CONTACT INFORMATION
    If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

  • Contains 2 Component(s) Recorded On: 08/02/2022

    Sponsored by Boston Scientific Corporation and Sirtex. Presented Wednesday 3 August 2022.

    This 100-level webinar targets trainees, residents, and other early career physicians who are interested in learning the basics of different Y90 methodologies, how and why to select one treatment method over another, and the step-by-step processes of Y90 treatment from start to finish. Faculty will share case examples from initial clinic visit, mapping, and follow up to illustrate decision making and common pitfalls. Faculty will also discuss new dosimetry software and outlooks on the future of personalize dosimetry.

    Learning Objectives

    • Define basic processes of different Y90 treatment methodologies
    • Evaluate which treatment is the most appropriate selection for different patients
    • Examine case examples
    MODERATORRiad Salem, MD, MBA
    MODERATORDave Liu, MD
    A Review of Dosimerty & Its ImportanceNima Kokabi, MD, FRCP
    Early Stage & Radseg Curative IntentEd Kim, MD
    PVT, Neoadjuvants & Conversion Sequencing for High Burden High ShuntDave Liu, MD
    Perspectives on Differences in Microsphere CharacteristicsMarnix Lam, MD
    Q&A and DiscussionAll

  • Contains 1 Component(s) Recorded On: 06/01/2022

    SIO2021 Hackathon Winner, Michelle Bardis, MD, PGY1, provides an update on her research (June 2022).

    SIO2021 Hackathon Winner, Michelle Bardis, MD, PGY1, provides an update on her research (June 2022).

  • Contains 30 Product(s)

    SIO2021 Conference Recordings

    SIO2021 Conference Recordings

  • Contains 1 Component(s)

    This recording is part of the SIO2021 Conference Recordings Bundle. (2-6 February 2021)

    This recording is part of the SIO2021 Conference Recordings Bundle. Click here to purchase the full bundle and save!

     MODERATORBob Lewandowski, MD
    Medical Oncologist Perspective Tom Karasic, MD
    Surgical Oncologist Perspective Doug Fraker, MD
    Hepatologist Perspective Veronica Loi, DO
    Interventional Oncologist Perspective Bob Lewandowski, MD
  • Contains 1 Component(s)

    This recording is part of the SIO2021 Conference Recordings Bundle. (2-6 February 2021)

    This recording is part of the SIO2021 Conference Recordings Bundle. Click here to purchase the full bundle and save!

    MODERATOR William Rilling, MD, FSIR
    Terminology for Oncological Outcome Measures Martijn Meijerink, MD, PhD
    Literature Studies and Registries Raj Shah, MD
    Building an IO Practice AJ Gunn, MD
    Value of IR from the C-Suite Perspective Matt Johnson, MD
  • Contains 1 Component(s)

    This recording is part of the SIO2021 Conference Recordings Bundle. (2-6 February 2021)

    This recording is part of the SIO2021 Conference Recordings Bundle. Click here to purchase the full bundle and save!

    MODERATOR Ronald Arellano, MD
    MODERATOR David Madoff, MD
    HCC Laura Crocetti, MD, PhD, EBIR
    mCRC Philippe Pereira, MD
    Lung William Moore, MD
    Renal Jeremy Durack, MD
    Spine & Bone  MK Jesse, MD